Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GDC-0980 + mFOLFOX6 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**GDC-0980 + mFOLFOX6 + bevacizumab** is a combination regimen used in oncology clinical trials, primarily for colorectal and other gastrointestinal cancers. GDC-0980 (apitolisib) is a dual class I PI3K/mTOR inhibitor, administered orally, with activity against solid tumors by blocking the PI3K/AKT/mTOR pathway, which is crucial for cell growth and survival[3][5]. mFOLFOX6 is a modified FOLFOX regimen involving intravenous oxaliplatin, leucovorin (folinic acid), and 5-fluorouracil, given in cycles[2][4][6]. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), reducing tumor angiogenesis[4]. Together, this combination is investigational and has been explored for metastatic gastrointestinal tumors, potentially offering synergistic cytotoxicity and antiangiogenic effects through complementary mechanisms.
- Other names
- apitolisibmFOLFOX6mFOLFOX-6mFOLFOX 6folinic acid fluorouracil oxaliplatinFOLFOX
02
Targets
PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)VEGFA (Vascular endothelial growth factor A)DNAmTOR (Mammalian target of rapamycin kinase)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)TS (Thymidylate synthase)
Beyond the preview
Go deeper on GDC-0980 + mFOLFOX6 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GDC-0980 + mFOLFOX6 + bevacizumab.